down arrow

QIAGEN NV

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: NL0015001WM6
USD
47.08
0.26 (0.56%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

46.5847.26

52 Week

37.6351.88
Valuation
Technical
Day's Volume

CASH

394.38 k

Shareholding (Mar 2025)

FII

29.48%

Held by 225 FIIs

DII

38.31%

Held by 50 DIIs

Promoter

0.25%

How big is QIAGEN NV?

22-Jun-2025

As of Jun 18, QIAGEN NV has a market capitalization of 10,202.95 million, with net sales of 2,002.88 million and a net profit of 93.68 million over the latest four quarters.

Market Cap: As of Jun 18, QIAGEN NV has a market capitalization of 10,202.95 million, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, QIAGEN NV reported net sales of 2,002.88 million and a net profit of 93.68 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, QIAGEN NV's shareholder's funds amounted to 3,567.34 million, while total assets were reported at 5,689.62 million.

Read More

What does QIAGEN NV do?

22-Jun-2025

QIAGEN N.V. is a holding company that provides Sample to Insight solutions in the Pharmaceuticals & Biotechnology industry, with a market cap of approximately $10.2 billion. As of March 2025, it reported net sales of $483 million and a net profit of $91 million.

Overview:<BR>QIAGEN N.V. is a holding company engaged in providing Sample to Insight solutions that transform biological samples into molecular insights, operating in the Pharmaceuticals & Biotechnology industry with a mid-cap market capitalization.<BR><BR>Financial Snapshot:<BR>Net Sales: 483 Million (Quarterly Results - Mar 2025) <BR>Net Profit: 91 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 10,202.95 Million (Mid Cap)<BR><BR>Key Metrics:<BR>P/E: 20.00 <BR>Dividend Yield: 2.90% <BR>Debt Equity: 0.13 <BR>Return on Equity: 14.43% <BR>Price to Book: 2.99<BR><BR>Contact Details:<BR>Address: Hulsterweg 82, VENLO None: 5912 PL <BR>Tel: ['31 77 3556600', '31 773 556666'] <BR>Fax: 31 77 3208409 <BR>Website: https://www.qiagen.com/

Read More

Who are in the management team of QIAGEN NV?

22-Jun-2025

As of March 2022, the management team of QIAGEN NV includes Mr. Lawrence Rosen (Chairman) and five independent members: Mr. Stephane Bancel, Dr. Metin Colpan, Prof. Dr. Ross Levine, Dr. Elaine Mardis, and Ms. Elizabeth Tallett, who guide the company's strategic direction and governance.

As of March 2022, the management team of QIAGEN NV includes the following members of the Board of Directors:<BR><BR>- Mr. Lawrence Rosen, Independent Chairman of the Supervisory Board<BR>- Mr. Stephane Bancel, Independent Member of the Supervisory Board<BR>- Dr. Metin Colpan, Independent Member of the Supervisory Board<BR>- Prof. Dr. Ross Levine, Independent Member of the Supervisory Board<BR>- Dr. Elaine Mardis, Independent Member of the Supervisory Board<BR>- Ms. Elizabeth Tallett, Independent Member of the Supervisory Board<BR><BR>These individuals play key roles in guiding the company's strategic direction and governance.

Read More

Is QIAGEN NV overvalued or undervalued?

20-Sep-2025

As of September 9, 2025, QIAGEN NV is fairly valued with a P/E ratio of 20 and a PEG ratio of 0.59, but has underperformed the S&P 500 with a 5-year return of -14.74%.

As of 9 September 2025, the valuation grade for QIAGEN NV has moved from expensive to fair, indicating a more favorable assessment of its market position. The company appears to be fairly valued at this time. Key valuation ratios include a P/E ratio of 20, an EV to EBIT of 19.95, and a PEG ratio of 0.59, which suggests that the stock is reasonably priced relative to its earnings growth potential.<BR><BR>In comparison to peers, QIAGEN NV's P/E ratio of 24.20 is higher than Hologic, Inc.'s P/E of 21.83, but lower than The Cooper Companies, Inc.'s P/E of 34.28, indicating a competitive standing within the industry. Despite this fair valuation, QIAGEN NV has underperformed against the S&P 500 over multiple periods, with a 5-year return of -14.74% compared to the S&P 500's 96.61%, highlighting potential concerns regarding its growth trajectory.

Read More

Is QIAGEN NV technically bullish or bearish?

07-Oct-2025

As of October 3, 2025, QIAGEN NV shows a mildly bullish trend overall, despite mixed signals from indicators and underperformance compared to the S&P 500 across multiple timeframes.

As of 3 October 2025, the technical trend for QIAGEN NV has changed from sideways to mildly bullish. The daily moving averages indicate a mildly bullish stance, while the weekly MACD and KST are mildly bearish, contrasting with the monthly indicators which are bullish. The Bollinger Bands also reflect a mildly bearish trend on the weekly timeframe but bullish on the monthly. <BR><BR>In terms of performance, QIAGEN has underperformed the S&P 500 over the 1-month, 1-year, 3-year, and 5-year periods, with returns of -1.24%, 4.79%, 6.73%, and -13.45% respectively, compared to the S&P 500's returns of 4.15%, 17.82%, 82.57%, and 100.56%. Overall, the current technical stance is mildly bullish, but the mixed signals from various indicators suggest caution.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.91 times

 
2

Poor long term growth as Operating profit has grown by an annual rate 5.15% of over the last 5 years

 
3

Positive results in Jun 25

4

With ROCE of 13.55%, it has a very expensive valuation with a 2.70 Enterprise value to Capital Employed

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 10,429 Million (Small Cap)

stock-summary
P/E

20.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

2.83%

stock-summary
Debt Equity

0.14

stock-summary
Return on Equity

12.29%

stock-summary
Price to Book

2.98

Revenue and Profits:
Net Sales:
534 Million
(Quarterly Results - Jun 2025)
Net Profit:
96 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
0.09%
0%
0.09%
6 Months
2.97%
0%
2.97%
1 Year
4.57%
0%
4.57%
2 Years
6.96%
0%
6.96%
3 Years
-6.49%
0%
-6.49%
4 Years
-13.14%
0%
-13.14%
5 Years
-2.49%
0%
-2.49%

QIAGEN NV for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is QIAGEN NV technically bullish or bearish?

As of 3 October 2025, the technical trend for QIAGEN NV has changed from sideways to mildly bullish. The daily moving averages indicate a mildly bullish stance, while the weekly MACD and KST are mildly bearish, contrasting with the monthly indicators which are bullish. The Bollinger Bands also reflect a mildly bearish trend on the weekly timeframe but bullish on the monthly. In terms of performance, QIAGEN has underperformed the S&P 500 over the 1-month, 1-year, 3-year, and 5-year periods, with returns of -1.24%, 4.79%, 6.73%, and -13.45% respectively, compared to the S&P 500's returns of 4.15%, 17.82%, 82.57%, and 100.56%. Overall, the current technical stance is mildly bullish, but the mixed signals from various indicators suggest caution....

Read More

Is QIAGEN NV technically bullish or bearish?

As of 3 October 2025, the technical trend for QIAGEN NV has changed from sideways to mildly bullish. The daily moving averages indicate a mildly bullish stance, while the weekly MACD and Bollinger Bands show mildly bearish signals. However, the monthly MACD and Bollinger Bands are bullish, suggesting some strength in the longer term. Overall, the mixed signals indicate a mildly bullish sentiment. In terms of performance, QIAGEN has underperformed the S&P 500 over the 1-month, 1-year, 3-year, and 5-year periods, but it has outperformed in the past week....

Read More

Is QIAGEN NV technically bullish or bearish?

As of 3 October 2025, the technical trend for QIAGEN NV has changed from sideways to mildly bullish. The daily moving averages indicate a mildly bullish stance, while the monthly MACD and Bollinger Bands also support a bullish outlook. However, the weekly MACD and KST are mildly bearish, suggesting some caution in the short term. The stock has shown a strong 1-week return of 6.61% compared to the S&P 500's 1.09%, but the longer-term returns are lagging, with a 5-year return of -10.55% versus the S&P 500's 100.56%. Overall, the current technical stance is mildly bullish, driven by daily moving averages and monthly indicators, despite mixed signals from weekly metrics....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
4.83%
EBIT Growth (5y)
5.15%
EBIT to Interest (avg)
10.44
Debt to EBITDA (avg)
0.91
Net Debt to Equity (avg)
0.13
Sales to Capital Employed (avg)
0.38
Tax Ratio
32.32%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
78.33%
ROCE (avg)
13.81%
ROE (avg)
14.15%
Valuation key factors
Factor
Value
P/E Ratio
20
Industry P/E
Price to Book Value
2.93
EV to EBIT
19.95
EV to EBITDA
14.57
EV to Capital Employed
2.70
EV to Sales
5.20
PEG Ratio
0.59
Dividend Yield
2.96%
ROCE (Latest)
13.55%
ROE (Latest)
14.47%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 83 Schemes (31.94%)

Foreign Institutions

Held by 225 Foreign Institutions (29.48%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 10.34% vs -7.23% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 5.95% vs 2.83% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "533.50",
          "val2": "483.50",
          "chgp": "10.34%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "185.50",
          "val2": "170.40",
          "chgp": "8.86%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "7.60",
          "val2": "7.30",
          "chgp": "4.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-14.10",
          "val2": "-8.00",
          "chgp": "-76.25%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "96.20",
          "val2": "90.80",
          "chgp": "5.95%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "254.90%",
          "val2": "261.60%",
          "chgp": "-0.67%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.66% vs -8.23% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -75.51% vs -19.35% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "1,978.20",
          "val2": "1,965.30",
          "chgp": "0.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "698.20",
          "val2": "650.60",
          "chgp": "7.32%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "43.80",
          "val2": "53.40",
          "chgp": "-17.98%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-405.60",
          "val2": "-47.30",
          "chgp": "-757.51%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "83.60",
          "val2": "341.30",
          "chgp": "-75.51%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "250.20%",
          "val2": "226.60%",
          "chgp": "2.36%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
533.50
483.50
10.34%
Operating Profit (PBDIT) excl Other Income
185.50
170.40
8.86%
Interest
7.60
7.30
4.11%
Exceptional Items
-14.10
-8.00
-76.25%
Consolidate Net Profit
96.20
90.80
5.95%
Operating Profit Margin (Excl OI)
254.90%
261.60%
-0.67%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 10.34% vs -7.23% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 5.95% vs 2.83% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
1,978.20
1,965.30
0.66%
Operating Profit (PBDIT) excl Other Income
698.20
650.60
7.32%
Interest
43.80
53.40
-17.98%
Exceptional Items
-405.60
-47.30
-757.51%
Consolidate Net Profit
83.60
341.30
-75.51%
Operating Profit Margin (Excl OI)
250.20%
226.60%
2.36%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 0.66% vs -8.23% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -75.51% vs -19.35% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About QIAGEN NV stock-summary
stock-summary
QIAGEN NV
Pharmaceuticals & Biotechnology
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Company Coordinates stock-summary
Company Details
Hulsterweg 82 , VENLO None : 5912 PL
stock-summary
Tel: 31 77 355660031 773 556666
stock-summary
https://www.qiagen.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."